Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GOSS 10.07.2024

Full Press ReleaseSEC FilingsOur GOSS Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • 12.06.2024 - BEST PRACTICES FOR MANAGING COUGH IN PAH PATIENTSRECEIVING INHALED THERAPIES
  • 12.06.2024 - A RETROSPECTIVE STUDY INVESTIGATING THE REAL-WORLD USE OF MONOTHERAPY IN PULMONARY ARTERIAL HYPERTENSION (PAH) IN THE US

Recent Filings

  • 11.12.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
  • 11.07.2024 - EX-99.1 EX-99.1
  • 11.07.2024 - 8-K Current report
PDF Version

SAN DIEGO--(BUSINESS WIRE)--Oct. 7, 2024--Gossamer Bio, Inc.(Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effectiveOctober 4, 2024, to five new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 221,000 shares of the Company’s common stock under theGossamer Bio, Inc.2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of$1.07per share, which is equal to the closing price of Gossamer’s common stock as reported by The Nasdaq Global Select Market onOctober 4, 2024. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive monthly installments thereafter, subject to each employee’s continued employment with Gossamer on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.

AboutGossamer Bio

Gossamer Biois a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241007084198/en/

For Investors and Media:Bryan Giraudo, Chief Operating Officer and Chief Financial OfficerGossamer Bio Investor Relationsir@gossamerbio.com

Source:Gossamer Bio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com